Biotech IV Monitor

GPCR — Structure Therapeutics Inc.

$3.5B market cap · 0 upcoming readouts tracked

Clinical trial readout dates for Structure Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced.

Market cap$3.5B
Cash & investments$1.24B~9 quarters at last loss rate
Recent 8-K filings1latest 2026-11-09

Target dates already passed

These dates have elapsed; the company may have reported, or guidance may have shifted.

Phase 3 Aleniglipron (GSBR-1290)
Type 2 Diabetes, obesity
October 24, 2025
Trial Planned

Cash position

Structure Therapeutics Inc. reported $1.24B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). Its net loss for that quarter was $145M; at that rate the cash would last about 9 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-09

Companies working on similar indications

Discussion

No messages yet. If you follow GPCR, you can start the conversation.
Track GPCR in real time
See live implied volatility for GPCR and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on GPCR
Contact — questions or corrections about GPCR: dukeupt@gmail.com